Acutis Biosciences is excited about its collaboration with SOPHiA GENETICS, a renowned cloud-native software company in the healthcare space and a leader in data-driven medicine and will leverage the SOPHiA DDM™ Platform (Data-Driven Medicine) to support genomic screening in hereditary cancers to enhance patient enrollment & stratification in oncology clinical trials and retrospective analyses.
The primary objective of this collaboration is to expedite the process for launching key clinical oncology trials by using SOPHiA DDM™ to aid clinical researchers
Ken Freedman, Chief Revenue Officer of SOPHiA GENETICS, emphasized their commitment to creating technologies and solutions that facilitate data-driven medicine. He believes the new assay developed by Acutis will empower clinical researchers to work more efficiently, providing them with comprehensive insights into their data. Ultimately, this advancement will benefit both current and future patients, as well as the healthcare industry as a whole.
By leveraging SOPHiA GENETICS' state-of-the-art technology, Acutis Biosciences aims to advance clinical research and treatment strategies for individuals affected by hereditary cancers. This optimized panel, a TruSight™ hereditary cancer panel is part of the ACUTIS ALIGN™ test menu who will empower researchers to gain a deeper understanding of genomic data, facilitating more targeted and personalized approaches to cancer treatment. Moreover, the assay will support retrospective analyses, shedding light on clinical outcomes and aiding in the discovery of drug targets.
In addition to improving the efficiency of clinical trials, the new assay will generate a comprehensive set of data and insights that will have far-reaching implications for clinical decision-making and future research. The availability of such robust information will enable researchers to make informed choices about treatment options and contribute to the advancement of cancer research as a whole.
The significance of this collaboration stems from the fact that approximately 20% of cancer patients have a family history of the disease. Next-generation sequencing (NGS) has emerged as the leading technology for SOPHiA GENETICS, which offers hereditary cancer solutions that utilize NGS-based applications, combining artificial intelligence (AI) and machine learning (ML) with patented technologies to analyze raw NGS data and deliver simplified insights. This cutting-edge technology enables clinical researchers to effectively characterize the intricate mutational landscape associated with major hereditary cancer disorders.
The collaboration between SOPHiA GENETICS and Acutis Biosciences represents a significant step forward in the field of genomic medicine and highlights the importance of data-driven medicine and its potential to transform healthcare by delivering personalized and targeted approaches to patient care. Acutis Biosciences aims to make a lasting impact on the lives of individuals affected by hereditary cancers and contribute to the continuous evolution of genomic medicine.
About Acutis Biosciences
Acutis Biosciences is a biomarker discovery provider to biopharmaceutical companies with next-generation multi-omics biomarker analysis solutions powered by machine learning (ML) and AI. With technology platforms in genomics and histopathology for the development and validation of state-of-the-art cancer molecular diagnostic assays in oncology, immuno-oncology, and infectious diseases, Acutis redefines conventions with a unique customer engagement model coupled with extraordinary science.
For more information
Troy Tremaine
Chief Commercial Officer
Senior Vice President
ttremaine@acutis.com